At last, the quite high (partial) vaccination rate among FMC’s vulnerable patients (>80%) and the Omicron variant’s mild effects have led to a reduction in excess mortality. The financial impact on the FME25 programme remained at unexpected low levels.
Nevertheless, 2022 is earmarked as seeing some continuation of the challenges (effects from excess mortality, staff shortages).
Our estimates were beaten by +4.2% (consensus: +0.6%) at the top-line and by +6.4% at the EBIT level (consensus: -1 ....
23 Feb 2022
A vaccination beneficiary
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A vaccination beneficiary
Fresenius Medical Care AG (FME:ETR) | 0 0 0.0%
- Published:
23 Feb 2022 -
Author:
Martin Schnee -
Pages:
5
At last, the quite high (partial) vaccination rate among FMC’s vulnerable patients (>80%) and the Omicron variant’s mild effects have led to a reduction in excess mortality. The financial impact on the FME25 programme remained at unexpected low levels.
Nevertheless, 2022 is earmarked as seeing some continuation of the challenges (effects from excess mortality, staff shortages).
Our estimates were beaten by +4.2% (consensus: +0.6%) at the top-line and by +6.4% at the EBIT level (consensus: -1 ....